Contact Us

The choice depends on whether you are studying SLC18B1's role as a putative polyamine vesicular transporter or its emerging functions in lysosomal/endosomal storage. The Knockout line is appropriate for asking whether SLC18B1 is required for the vesicular accumulation of polyamines (spermine, spermidine) — SLC18B1 is the most recently identified SLC18 family member with proposed polyamine transport activity. Overexpression is useful for testing transport activity or for substrate identification. For polyamine biology research, the EDITGENE SLC18B1 Knockout in HCT 116 enables study of vesicular polyamine handling in a cancer context — polyamines are essential for proliferating cells, including colorectal cancer cells. Rescue with wild-type or transport-deficient SLC18B1 is the standard specificity control. SLC18A1 (VMAT1) and SLC18A2 (VMAT2) paralog expression analysis aids interpretation given the family's vesicular transport biology.

Yes, with attention to vesicular targeting: • Construct design: use a codon-modified SLC18B1 sequence with a small C-terminal tag (FLAG, HA). SLC18B1 has 12 transmembrane domains in the canonical SLC18 architecture. • Vesicular localization validation: confirm intracellular vesicular localization by imaging before functional assays. • Transport-deficient rescue: substrate-binding mutations enable distinguishing predicted polyamine transport from other functions. • Functional readout: rescue should restore phenotypes identified during knockout characterization (polyamine handling, vesicular function). HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC15A4 (PHT1)'s role as an endolysosomal histidine/peptide transporter or its emerging functions in innate immunity and SLE pathogenesis. The Knockout line is the standard tool for asking whether SLC15A4 is required for endolysosomal nucleotide delivery to TLR7/TLR9 and NOD1/NOD2 — SLC15A4 transports histidine and small peptides into the endolysosomal lumen and is required for nucleic acid sensor activation. Overexpression is useful for studying SLC15A4 in TLR signaling or autoimmunity contexts. For autoimmunity research, the EDITGENE SLC15A4 Knockout in HCT 116 is particularly valuable — SLC15A4 has been identified as a systemic lupus erythematosus (SLE) susceptibility gene through GWAS, and Slc15a4-deficient mice are protected from lupus models. TLR7/TLR9 signaling readouts (IFN-α, IRF7 activation) characterize SLC15A4's adaptor-like role. Rescue with wild-type or transport-deficient SLC15A4 enables structure-function studies. SLC15A4 is being investigated as a therapeutic target for SLE.

Yes. SLC15A4 rescue experiments are well-established for immune signaling research: • Construct design: use a codon-modified SLC15A4 sequence with a small C-terminal tag (FLAG, HA). SLC15A4 has 12 transmembrane domains with endolysosomal targeting determinants. • Endolysosomal localization validation: confirm endolysosomal localization by LAMP1 co-staining before functional assays. • Transport-deficient rescue: substrate-binding pocket mutations enable distinguishing histidine/peptide transport from adaptor/scaffolding functions in TLR signaling. • Functional readout: rescue should restore endosomal TLR7/TLR9 signaling activity and histidine/peptide transport. HCT 116 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SHFL (RyDEN, Repressor of Yield of DENV)'s role as an interferon-stimulated antiviral factor or its emerging functions in cellular RNA biology. The Knockout line is the standard tool for asking whether SHFL is required for restricting viral replication — SHFL is an ISG with broad antiviral activity against dengue virus, Zika virus, HIV-1, SARS-CoV-2, and other RNA viruses. Overexpression is useful for studying SHFL-induced antiviral mechanisms. For antiviral immunity research, the EDITGENE SHFL Knockout in HEK293 enables study of intrinsic antiviral defense and ISG function. SHFL functions through inhibiting viral programmed ribosomal frameshifting (e.g., HIV-1 Gag-Pol frameshift) and other translation-level antiviral mechanisms. Rescue with wild-type or domain-deletion SHFL enables structure-function studies. The knockout is valuable for studying virus-host interactions in respiratory and arbovirus research.

Yes. SHFL rescue experiments are well-established for antiviral research: • Construct design: use a codon-modified SHFL sequence with a small C-terminal tag (FLAG, HA). SHFL contains zinc finger domains critical for RNA binding — preserve these elements. • Domain-deletion rescue: zinc finger or other domain mutations enable structure-function studies separating RNA binding from antiviral activities. • Antiviral activity readout: rescue should restore restriction of dengue, Zika, or HIV-1 replication and inhibition of programmed ribosomal frameshifting in dual-luciferase reporter assays. • ISG response context: SHFL rescue interpretation should consider IFN signaling status of cells. HEK293 transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying SLC12A1 (NKCC2)'s role as the apical Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb or modeling Bartter syndrome type 1. The Knockout line is the standard tool for asking whether NKCC2 is required for these transport activities — NKCC2 is the principal Na⁺ reabsorption transporter in the renal thick ascending limb and the molecular target of loop diuretics (furosemide, bumetanide). Overexpression is useful for studying disease-associated mutations or for testing diuretic specificity. Important context: NKCC2 is principally expressed in renal thick ascending limb — HeLa is not the physiological context for NKCC2 function. The EDITGENE Knockout in HeLa is most useful for in vitro biochemistry, structure-function studies, and as a clean background for heterologous NKCC2 reconstitution. SLC12A1 mutations cause Bartter syndrome type 1 (antenatal Bartter syndrome with severe salt-wasting) — disease variant rescue enables genotype-function studies. Rescue with wild-type, transport-deficient, or diuretic-resistant NKCC2 variants enables comprehensive functional characterization.

Yes. NKCC2 rescue experiments are well-established for diuretic pharmacology and Bartter disease research: • Construct design: use a codon-modified SLC12A1 sequence with a small C-terminal tag (FLAG, HA). NKCC2 has 12 transmembrane domains with a large cytoplasmic C-terminus. • Splice variant-specific rescue: NKCC2-A, NKCC2-B, NKCC2-F variants have distinct kinetic properties — separate rescue enables variant-specific characterization. • Bartter syndrome rescue: patient-derived SLC12A1 mutations enable comprehensive disease genotype-function studies. • Functional readout: rescue should restore Na⁺-K⁺-2Cl⁻ cotransport activity measured by ⁸⁶Rb⁺ or ³⁶Cl⁻ flux assays. HeLa transduces efficiently with lentivirus and supports stable rescue line generation.

The choice depends on whether you are studying S1PR1 (sphingosine 1-phosphate receptor 1)'s role as the principal S1P receptor in glioma biology or in modeling fingolimod (FTY720) mechanism in multiple sclerosis contexts. The Knockout line is the standard tool for asking whether S1PR1 is required for these processes — S1PR1 is the most broadly expressed S1P receptor and the principal target of fingolimod (Gilenya), the first oral disease-modifying therapy for MS. Overexpression is useful for studying receptor signaling in heterologous contexts or for testing S1PR1-selective compounds. For glioma and MS research, the EDITGENE S1PR1 Knockout in U251 MG is particularly relevant — U251 MG is a widely-used glioblastoma model, and S1PR1 has been implicated in glioma cell migration, invasion, and crosstalk with tumor immune microenvironment. Rescue with wild-type or signaling-deficient S1PR1 enables structure-function studies. The knockout serves as a critical genetic specificity control for fingolimod and next-generation S1P receptor modulators (siponimod, ozanimod, ponesimod) in MS therapeutic development.

Yes. S1PR1 rescue experiments are well-established in pharmacology research: • Construct design: use a codon-modified S1PR1 sequence with a small intracellular C-terminal tag (FLAG, HA). S1PR1 is a seven-transmembrane GPCR — preserve extracellular ligand-binding pocket. • Signaling-deficient rescue: Gi-coupling-deficient mutations (e.g., DRY motif) separate ligand binding from intracellular signaling functions. • Internalization-deficient rescue: cytoplasmic tail phosphorylation site mutations affect receptor internalization — relevant for distinguishing fingolimod (functional antagonist via internalization) from competitive antagonist mechanisms. • Functional readout: rescue should restore S1P-induced cAMP modulation, ERK activation, and migration/invasion phenotypes in U251 MG glioma context. U251 MG transduces efficiently with lentivirus and supports stable rescue line generation; the glioblastoma background enables glioma-relevant S1PR1 functional studies.

The choice depends on whether you are studying SETMAR (Metnase)'s role as a histone H3K36 methyltransferase fused to a transposase-derived domain or its functions in DNA double-strand break repair. The Knockout line is the standard tool for asking whether SETMAR is required for these activities — SETMAR is a primate-specific gene formed by fusion of a SET histone methyltransferase domain with a Mariner transposase-derived domain, functioning in non-homologous end joining and HR repair pathway regulation. Overexpression is useful for studying SETMAR's reported roles in chemotherapy resistance. For DNA repair research, the EDITGENE SETMAR Knockout in HAP1 enables study of this unique fusion enzyme's contributions to genome stability. Rescue with wild-type, catalytically-dead (SET domain), or transposase-domain-mutated SETMAR enables dissection of the dual functional domains. SETMAR has emerging interest as a chemotherapy resistance modifier and potential cancer target.

Yes. SETMAR rescue experiments require attention to its bipartite functional architecture: • Construct design: use a codon-modified SETMAR sequence with a small C-terminal tag (FLAG, HA). SETMAR contains an N-terminal SET methyltransferase domain and C-terminal Mariner transposase-derived domain — both are functional. • SET-dead rescue: catalytic SET domain mutations abolish methyltransferase activity and serve as specificity control for H3K36 methylation function. • Transposase-dead rescue: catalytic residue mutations in the Mariner domain abolish DNA cleavage/strand transfer activity, enabling dissection of DNA-processing functions. • Functional readout: rescue should restore H3K36me2 deposition at DSB sites and DNA repair efficiency. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying S1PR5 (sphingosine 1-phosphate receptor 5)'s role in NK cell trafficking, oligodendrocyte biology, or its emerging functions in cancer. The Knockout line is appropriate for asking whether S1PR5 is required for S1P-mediated signaling in non-immune contexts. Overexpression is useful for studying S1PR5 in heterologous systems or for testing receptor-selective agonists. Important consideration: S1PR5 is primarily expressed on NK cells, CD8+ T effector memory cells, and oligodendrocytes — HAP1 is not the physiological context for S1PR5. The EDITGENE Knockout in HAP1 is most useful for in vitro biochemistry, heterologous expression studies, and as a clean background for S1PR family-selective compound testing. Rescue with wild-type or signaling-deficient S1PR5 is the standard specificity control. For physiological S1PR5 research, NK cell or oligodendrocyte models are more appropriate.

Yes. S1PR5 rescue experiments require attention to GPCR topology: • Construct design: use a codon-modified S1PR5 sequence with a small intracellular C-terminal tag (FLAG, HA). S1PR5 is a seven-transmembrane GPCR — N-terminal tags after the signal peptide are tolerated. • Surface localization validation: confirm plasma membrane localization by cell surface staining before signaling assays. • Signaling-deficient rescue: DRY motif mutations or specific intracellular loop mutations disrupt G-protein coupling — standard controls for receptor-mediated signaling. • Functional readout: rescue should restore S1P-induced signaling (cAMP measurement, ERK phosphorylation) and S1PR5-selective compound responses. HAP1-specific considerations: • Diploidization: HAP1 cells gradually diploidize during extended culture — confirm ploidy by flow cytometry at the time of phenotypic assay. • Integration site sensitivity: position effects on transgene expression are more pronounced in near-haploid backgrounds; generating multiple independent rescue clones is strongly recommended. • Transduction efficiency: HAP1 transduces with lentivirus at moderate efficiency — increase MOI compared to standard immortalized lines.

The choice depends on whether you are studying SGK3 (serum and glucocorticoid-regulated kinase 3)'s role as a PI3K-dependent kinase activated by endosomal PI(3)P or its emerging functions as a compensatory pathway for AKT-targeted cancer therapy. The Knockout line is the standard tool for asking whether SGK3 is required for these activities — SGK3 is uniquely activated by PI(3)P (via its PX domain) and PDK1 phosphorylation, distinguishing it from AKT and other SGK family members. Overexpression is useful for studying SGK3 in cancer contexts where it provides PI3K signaling redundancy. For PI3K-AKT pathway research, the EDITGENE SGK3 Knockout in HAP1 is highly informative — SGK3 has emerged as a critical bypass pathway for AKT inhibitor resistance in cancer, particularly in PIK3CA-mutant tumors. Rescue with wild-type, kinase-dead (K191A), or PX-domain-mutant (PI(3)P-binding-deficient) SGK3 enables comprehensive structure-function studies. The knockout serves as a critical specificity control for SGK3 inhibitors (14h, others) in cancer drug development.